Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 9/20 | 0.60 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.52 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.50 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CASP2 | P42575 | 1/20 | 0.48 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23974151 | 1.00 | FAAH (0.60) | FAAHHSP90AA1MEN1KMT2ATP53 | |
| SCHEMBL23718538 | 1.00 | FAAH (0.60) | FAAHHSP90AA1MEN1KMT2ATP53 | |
| SCHEMBL21065315 | 0.98 | FAAH (0.57) | FAAHHSP90AA1MEN1KMT2ATP53 | |
| SCHEMBL29060568 | 0.96 | FAAH (0.64) | FAAHHSP90AA1MEN1KMT2ATP53 | |
| SCHEMBL9664810 | 0.96 | FAAH (0.64) | FAAHHSP90AA1MEN1KMT2ATP53 | |
| SCHEMBL9664722 | 0.96 | FAAH (0.64) | FAAHHSP90AA1MEN1KMT2ATP53 | |
| SCHEMBL5200631 | 0.96 | FAAH (0.64) | FAAHHSP90AA1MEN1KMT2ATP53 | |
| SCHEMBL7520244 | 0.96 | FAAH (0.64) | FAAHHSP90AA1MEN1KMT2ATP53 | |
| SCHEMBL9664822 | 0.96 | FAAH (0.64) | FAAHHSP90AA1MEN1KMT2ATP53 | |
| SCHEMBL7345186 | 0.94 | FAAH (0.61) | FAAHHSP90AA1MEN1KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1032587-B2 | NOVEL EXENDIN AGONIST COMPOUNDS | AMYLIN PHARMACEUTICALS INC (US) | 2013-03-13 | — | — | EP | disclosed |
| US-7696161-B2 | Exendin agonist compounds | AMYLIN PHARMACEUTICALS, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-20090029913-A1 | Novel exendin agonist compounds | AMYLIN PHARMACEUTICALS, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| EP-1941900-A1 | Novel exendin agonist compounds | Amylin Pharmaceuticals, Inc. (US) | 2008-07-09 | — | — | EP | disclosed |
| EP-1938830-A1 | Novel exendin agonist compounds | Amylin Pharmaceuticals, Inc. (US) | 2008-07-02 | — | — | EP | disclosed |
| US-20080119393-A1 | Novel exendin agonist compounds | AMYLIN PHARMACEUTICALS, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| EP-1032587-B1 | NOVEL EXENDIN AGONIST COMPOUNDS | AMYLIN PHARMACEUTICALS INC (US) | 2008-01-16 | — | — | EP | disclosed |
| US-7223725-B1 | Exendin agonist compounds | AMYLIN PHARMACEUTICALS, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-7220721-B1 | Exendin agonist peptides | AMYLIN PHARMACEUTICALS, INC. (US) | 2007-05-22 | — | — | US | disclosed |
| EP-1032587-A4 | NOVEL EXENDIN AGONIST COMPOUNDS | AMYLIN PHARMACEUTICALS INC (US) | 2002-04-10 | — | — | EP | disclosed |
| EP-1066314-A1 | NOVEL EXENDIN AGONIST COMPOUNDS | AMYLIN PHARMACEUTICALS, INC. (US) | 2001-01-10 | — | — | EP | disclosed |
| EP-1032587-A1 | NOVEL EXENDIN AGONIST COMPOUNDS | AMYLIN PHARMACEUTICALS, INC. (US) | 2000-09-06 | — | — | EP | disclosed |
| WO-1999025727-A2 | NOVEL EXENDIN AGONIST COMPOUNDS | AMYLIN PHARMACEUTICALS, INC. (US) | 1999-05-27 | — | — | WO | disclosed |
| WO-1999025728-A1 | NOVEL EXENDIN AGONIST COMPOUNDS | AMYLIN PHARMACEUTICALS, INC. (US) | 1999-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119393-A1 | Novel exendin agonist compounds | GLP1R, GIPR, GPR119 | FAAH 913/4885HSP90AA1 3208/4885MEN1 658/4885 |
| US-20090029913-A1 | Novel exendin agonist compounds | GLP1R, GIPR, GPR119 | FAAH 913/4885HSP90AA1 3208/4885MEN1 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.